Proposed pharmacological interventions for DNMT3A-mutant AML include hypomethylating agents20, induction of apoptosis and/or necroptosis21, or targeting genes and/or pathways activated in DNMT3A-R882-mutant cells, such as DOT1L22 and mTOR23. This evidence concerns the gene DNMT3A and acute myeloid leukemia.